Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
Status:
NOT_YET_RECRUITING
Trial end date:
2030-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if the drug ropeginterferon alfa-2b can be used safely to treat patients with a JAK2 mutation and high risk features, but do not yet have a myeloproliferative neoplasm. The main questions it aims to answer are:
* Can we enroll 12 patients with JAK2 mutations and high risk features without a myeloproliferative neoplasm on a clinical trial evaluating the drug ropeginterferon?
* Is ropeginterferon safe to use in these patients?
Participants will:
* Receive ropeginterferon as an injection under the skin once every 4 weeks
* Visit the clinic every 1-3 months for checkups and tests